daraxonrasib

Daraxonrasib (RMC-6236) is an orally bioavailable, small molecule, noncovalent pan-RAS inhibitor designed to target the active, GTP-bound form of mutant and wild-type KRAS, NRAS, and HRAS proteins. It acts by forming a tri-complex with cyclophilin A and the active state of RAS proteins (RAS(ON)), thereby inhibiting downstream signaling pathways critical for tumor growth in cancers driven by oncogenic RAS mutations. Daraxonrasib is derived from sanglifehrin A using structure-guided design and demonstrates broad antitumor activity across multiple preclinical models. It is being developed primarily for solid tumors harboring various oncogenic RAS mutations—including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer—with ongoing clinical trials in these indications.

Brand names

RASONQUE

Other names

daraxonrasib